Sumitomo Pharma in the World
Sumitomo Pharma’s Three Strengths
  • R&D Capabilities01
  • Human Resources02
  • Global Business Platforms03
  • Small molecule

    Molecular design/

    synthesis based on

    accumulated

    experience/

    know-how

  • Regenerative medicine/cell therapy

    Know-how acquired

    by pioneering

    initiatives

  • Non-pharmaceutical(Frontier)

    To be developed in

    the mental resilience

    area

  • Other modalities

    Pursuit of optimal

    modalities

  • Psychiatry &Neurology Area
  • Oncology Area
  • Other Areas *
*Women's health issues, urological diseases, diabetes, rare diseases, infectious diseases
With a focus on the Psychiatry & Neurology and Oncology as priority disease areas, Sumitomo Pharma Group (the “Group”) will contribute to the betterment of healthcare and fuller lives of people worldwide through diverse approaches, including pharmaceutical products, regenerative medicine/cell therapy, and non-pharmaceutical solutions. In other areas, too, the Group will leverage its assets to deliver value to patients.With this, the Group aims to establish itself as a Global Specialized Player by 2033.
 
  • Implementing Health and Safety Risk Assessments
  • Providing Opportunities for Growth
  • Promoting Health Management
  • Promoting Work Style Innovation
  • Supporting Mental Wellbeing
  • Achieving Work-Life Balance
  • Preventing of Overwork
  • Promoting Diversity and Inclusion
  • Operating of Consultation Desks and Hotlines
  • Supporting Women’s Active Participation
At Sumitomo Pharma, we have diligent and honest human resources with resilient and detailed execution and a framework to utilize individual employee’s capabilities. We build a strong corporate culture and instill professionalism in our staff through our HR management framework, which brings out the best in talents who are highly capable of achieving results based on their expertise and our research project system, which develops project leaders, as well as our company-wide learning and development program. In addition, as part of our initiatives to further strengthen our human resources, we are working to nurture a corporate culture imbued with an enterprising, promote Project CHANTO, develop leaders and DX human resources, as well as to enhance diversity and inclusion targeting active participation by a varied work force.
Sumitomo Pharma – a company with global business platforms
Sumitomo Pharma has established strong business foundations in Japan, the United States, and China, including local HQ, sales, and R&D functions.
  • North America

    A solid business operation system with an excellent management team that can always communicate closely with the Company

    Know-hows in development and sales in the psychiatry and neurology area

    Strong sales structure through partnering

  • Japan

    Sales foundation built by MRs with high expertise in diabetes, psychiatry and neurology area, etc.

  • China/Asia

    Track record of launching competitive in-house products in the areas of infectious diseases and psychiatry and neurology as the third pillar

In addition to the above, Japan and the U.S. have healthcare technology platforms (DrugOME and Digital Innovation) that support the improvement of the probability of success in the research and development and the business return on investment.

Sumitomo Pharma promotes collaboration with partners in Europe and other regions.

Copyright @2016 住友制药. All rights reserved  (沪)  -非经营性-2016-0021  沪ICP备16016494号-3   沪公网安备 31010102002939号
You are leaving the official website of
Sumitomo Pharma (Suzhou) Co., Ltd.

You are about to leave the official website of Sumitomo Pharma (Suzhou) Co., Ltd. and be redirected to a third-party website. Please be aware of the risks involved.